Inflammasome Inhibition in Myocardial Infarction Reduces Early Reperfusion Injury and Suppresses Systemic Plaque Activation

Q: What does this research mean for the field?

NLRP3 inflammasome inhibition with MCC950 reduces myocardial infarct size and early reperfusion injury while suppressing remote atherosclerotic plaque activation following myocardial infarction. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Santosh Karnewar; The Anh Nguyen; Koya Ozawa; Weiting Huang; Onur Varli; Matteo Morello; Emma L. Lindner; Eli V. Casarez; Aris Xie; José A. López; Jazmin Kelly; Stefano Toldo; Antonio Abbate; Jonathan R. Lindner

doi:10.1016/j.atherosclerosis.2026.121848

July 1, 2026AtherosclerosisOpen Access

Inflammasome Inhibition in Myocardial Infarction Reduces Early Reperfusion Injury and Suppresses Systemic Plaque Activation

View Full Paper

Ask AI

Bookmark

Share

Atherosclerosis published a graphical abstract

Its licence doesn't allow us to show a copy here.

View on journal site ↗

Key Points

To investigate whether pharmacologic inhibition of the NLRP3 inflammasome reduces acute myocardial ischemia-reperfusion injury and suppresses remote systemic atherosclerotic plaque activation.
Subjected hyperlipidemic Ldlr −/− Apobec1 −/− (DKO) mice to closed-chest left anterior descending (LAD) coronary artery ischemia-reperfusion.
Administered the selective NLRP3 inhibitor MCC950 or vehicle control at reperfusion and evaluated cardiac function, tissue inflammation, and microvascular activation using serial echocardiography, contrast molecular imaging, intravital microscopy, and flow cytometry up to 28 days post-infarction.
MCC950 treatment reduced myocardial infarct size on day 3 by more than 50% compared to controls (11±4% vs 30±5% of the risk area, p<0.01).
Treatment suppressed myocardial inflammatory leukocyte recruitment, significantly reducing the proportion of CD45+ cells that were pro-inflammatory Ly6 hi monocytes (18.9±8.3% vs 35.6±10.5%, p=0.05).
Sustained MCC950 administration attenuated remote brachiocephalic artery plaque activation at 28 days, reducing overall atherosclerotic lesion size and Galectin-3-positive inflammatory cell infiltration while increasing fibrous cap alpha-SMA+ area.

Implication

Preclinical study demonstrates that NLRP3 inflammasome inhibition reduces myocardial infarct size and remote plaque activation in hyperlipidemic mice, indicating potential for dual cardioprotection.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Karnewar et al. (2026) studied this question.

synapsesocial.com/papers/6a5b39a28167787360d24f87 https://doi.org/10.1016/j.atherosclerosis.2026.121848

View Full Paper

Ask AI

Bookmark

Share

Inflammasome Inhibition in Myocardial Infarction Reduces Early Reperfusion Injury and Suppresses Systemic Plaque Activation

Atherosclerosis published a graphical abstract

Key Points

Implication

Abstract

Discussion

Cite This Study

Inflammasome Inhibition in Myocardial Infarction Reduces Early Reperfusion Injury and Suppresses Systemic Plaque Activation

Atherosclerosis published a graphical abstract

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading